HuMax-CD4 in refractory mycosis fungoides

This study is an open-label, dose escalation, followed by double-blinded, randomized, two-dose parallel group, multi-center clinical trial of HuMax-CD4, a fully human monoclonal anti-CD4 antibody, in patients with mycosis fungoides type CTCL (stage IB-IVB) who are refractory or intolerant to bexarotene and one other standard therapy.

You may be eligible to participate in this study if you:

• Have a diagnosis of mycosis fungoides
• Are resistant to at least two prior therapies

This is a partial list of eligibility requirements. For more information about your specific eligibility and requirements of participation, call the contact number provided.